Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

172 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Eligibility Leukemia, Myeloid New Model StudyXYZ - Eligibility Leukemia, Myeloid NCT00512083

- 10.01.18 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Description Study Eligibility Leukemia, Myeloid New Model StudyXYZ

Eligibility Leukemia, Myeloid NCT00512083

- 10.01.18 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia; Eligibility ODM derived from: https://clinicaltrials.gov/show/NCT00512083

Eligibility Philadelphia Positive Acute Lymphoblastic Leukemia NCT00199186

- 31.07.17 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT00199186

Leukemia Daunorubicin Cytarabine Oblimersen NCT00085124 CALGB - Secondary Form

- 29.07.17 - 1 Formular, 1 Itemgruppe, 17 Datenelemente, 1 Sprache
Itemgruppe: CCRR MODULE
CALGB: C-215 Secondary Form NCT00085124 Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B229FC8D-B88E-5150-E034-0003BA12F5E7

Leukemia Daunorubicin Cytarabine Oblimersen NCT00085124 CALGB - Follow-Up: NEW PRIMARY CANCER

- 27.07.17 - 1 Formular, 1 Itemgruppe, 16 Datenelemente, 1 Sprache
Itemgruppe: New primary cancer
CALGB: C-1001 NEW PRIMARY CANCER FORM Leukemia NCT00085124 Follow-Up - CALGB: C-1001 NEW PRIMARY CANCER FORM - 2076934v3.0 Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B229FEB2-6C43-5155-E034-0003BA12F5E7

Leukemia Daunorubicin and Cytarabine NCT00085124 CALGB - Tissue bank specimen routing form

- 25.07.17 - 1 Formular, 3 Itemgruppen, 32 Datenelemente, 1 Sprache
Itemgruppen: Specimen information, Laboratory only, CCRR MODULE
CALGB: LEUKEMIA TISSUE BANK SPECIMEN ROUTING FORM Leukemia NCT00085124 Pathology - CALGB: LEUKEMIA TISSUE BANK SPECIMEN ROUTING FORM - 2076722v3.0 Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B229F365-AE89-5149-E034-0003BA12F5E7

AML Daunorubicin Cytarabine NCT00085124 CALGB - OFF TREATMENT NOTICE

- 21.07.17 - 1 Formular, 1 Itemgruppe, 19 Datenelemente, 1 Sprache
Itemgruppe: Off Treatment
CALGB: OFF TREATMENT NOTICE Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Leukemia NCT00085124 Off Treatment - CALGB: OFF TREATMENT NOTICE - 2076876v3.0 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B229F9FE-3D25-514D-E034-0003BA12F5E7

Eligibility Myelogenous Leukemia, Acute NCT00374296

- 15.05.17 - 1 Formular, 2 Itemgruppen, 17 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00374296

Eligibility Myeloblastic Leukemia NCT00799799

- 14.05.17 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells; ODM derived from: https://clinicaltrials.gov/show/NCT00799799

Eligibility Leukemia NCT00075010

- 04.10.16 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes; ODM derived from: https://clinicaltrials.gov/show/NCT00075010

Eligibility Advanced Cancers NCT01653717

- 10.09.16 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT01653717

Eligibility Leukemia NCT00022126

- 23.07.16 - 1 Formular, 1 Itemgruppe, 31 Datenelemente, 1 Sprache
Itemgruppe: Criteria
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00022126

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video